Clinical Trial News Archive - April 2021
April 1, 2021
April 3, 2021
April 5, 2021
April 6, 2021
- FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
- NeuroRx Announces Zyesami (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
April 7, 2021
- Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine
- NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines
- Positive Results from the Sutimlimab Pivotal Trial for People with Cold Agglutinin Disease Published in New England Journal of Medicine
April 8, 2021
April 9, 2021
April 12, 2021
- Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV (casirivimab with imdevimab)
- Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
- Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
April 13, 2021
April 14, 2021
April 15, 2021
April 16, 2021
- Lilly Requests Revocation of Emergency Use Authorization for Bamlanivimab Alone to Complete Transition to Bamlanivimab and Etesevimab Together for Treatment of COVID-19 in the U.S.
- FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
April 19, 2021
April 21, 2021
- Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
- Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology
April 23, 2021
- Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
- Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
- The New England Journal of Medicine Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
April 26, 2021
April 27, 2021
April 28, 2021
- Amgen Provides Updated Information on Lumakras (sotorasib) Dose Comparison Study
- Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
- New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
- UCB Announces PDUFA Date for Bimekizumab
April 29, 2021
- Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
- Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral Korsuva in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
April 30, 2021
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.